Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-24-095507
Filing Date
2024-11-07
Accepted
2024-11-07 17:27:10
Documents
14
Period of Report
2024-08-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT TO FORM 8-K ea022043401-8ka_estrella.htm   iXBRL 8-K/A 33328
  Complete submission text file 0001213900-24-095507.txt   257882

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE esla-20240814.xsd EX-101.SCH 3838
3 XBRL DEFINITION FILE esla-20240814_def.xml EX-101.DEF 26723
4 XBRL LABEL FILE esla-20240814_lab.xml EX-101.LAB 36908
5 XBRL PRESENTATION FILE esla-20240814_pre.xml EX-101.PRE 25347
16 EXTRACTED XBRL INSTANCE DOCUMENT ea022043401-8ka_estrella_htm.xml XML 6583
Mailing Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET, SUITE 370 EMERYVILLE CA 94608 (510) 318-9098
Estrella Immunopharma, Inc. (Filer) CIK: 0001844417 (see all company filings)

EIN.: 861314502 | Fiscal Year End: 0630
Type: 8-K/A | Act: 34 | File No.: 001-40608 | Film No.: 241437230
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)